SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026.

SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026

SLS009, alternatively known as tambiciclib, is a selective CDK9 inhibitor. Put simply, this is a treatment designed to stop a specific “worker” protein in human cells called CDK9. SELLAS said it will present the data in a poster session. That is, instead of giving a formal speech on the stage at the San Diego Convention Center, the company will only display a printed poster.

The poster, titled “Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 levels in AML cell lines,” centers on the drug’s mechanism of action in acute myeloid leukemia, or AML, the company said in a press release statement. According to preclinical data, said SELLAS, SLS009 retained its activity in AML models carrying ASXL1 and TP53 mutations. To the company’s experts, this behavior underscores the drug’s potential to address patient populations that currently have very limited treatment options.

Earlier on March 12, SELLAS enrolled its first patient in a newly diagnosed, first-line AML trial of SLS009 in combination with venetoclax and azacitidine. This came after the FDA guidance that recommended this expansion after the drug met all endpoints in its completed Phase 2 trial in relapsed/refractory (r/r) AML. In the trial, the drug exceeded the pre-specified 20% overall response rate threshold with favorable safety and tolerability.

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is a clinical-stage biopharmaceutical company that develops cancer immunotherapies. Its lead product candidate is galinpepimut-S, a peptide-based immunotherapy designed to treat hematologic cancers and solid tumors.

While we acknowledge the risk and potential of SLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SLS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Robinhood Stocks with High Potential and 15 Best Forever Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.